Co-occurring genomic alterations, particularly in tumor suppressor genes such as TP53 and STK11, have emerged as determinants of the molecular and clinical heterogeneity of lung cancer with actionable genomic alterations (AGAs), including in patients with ALK fusion [47]. The gene discussed is ALK; the disease is lung cancer.